GLP-1 RAs, originally developed for glycemic control in type 2 diabetes, have demonstrated mechanistic plausibility and emerging clinical efficacy in modulating key pathophysiological processes implicated in depression, including insulin resistance, neuroinflammation, and reward system dysregulation. The gene discussed is INS; the disease is major depressive disorder.